GetFIT Lifestyle partners with Dante to bring the power of genomics to the world of fitness
– Collaboration unveiled at the RiminiWellness conference on June 3, 2022 –
MILAN, Italy, June 06, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, partners with GetFIT Lifestyle, the first Italian fitness group, to offer Dante’s Scientific Fitness Reports to the more than 30,000 GetFIT Lifestyle members. The goal of this partnership is to personalize an individual's physical exercise routine based on their genetic needs rather than the traditional approach based on superficial physical characteristics or taste, ushering in a new frontier of health where genetics meets the world of fitness.
Beginning July 1, 2022, GetFIT will offer Scientific Fitness Reports within its fitness clubs to the more than 30,000 active members and all interested parties exclusively in Italy and Europe. Genetic variants are differences in DNA between people. The Dante Genomics report explains how specific genetic variants in one's DNA can influence one's physical aptitude and metabolism, making this an extremely useful diagnostic tool now and in the future.
The information obtained from the analysis of the genes of an individual will for the first time the ability to formulate a plan with the support of the GetFIT certified instructors to optimize a training regimen in an effective and healthy way with the goal to live a longer, healthier and more energetic life.
"We are excited to partner with GetFIT on this progressive collaboration to bring valuable genomic information to the world of fitness,” said Andrea Riposati, CEO of Dante Genomics. “At Dante, we often say ‘personalized medicine needs personalized data,’ and I am confident that our innovative genomic tests will mean a more personalized fitness regimen and training plan for all GetFIT customers uniquely tailored to their DNA.”
"For almost 40 years, the GetFIT Group has been taking care of people's well-being. Present in Milan since 1984 with its fitness centers with swimming pools and thermarium and over 30,000 active members, our Mission is to inspire people to choose and maintain a healthy and active lifestyle and to feel good about themselves, through paths suitable for everyone and designed on the needs of each one,” said Livio Leardi, GetFIT Founder. “Being able to participate as a partner of Dante in this innovative project will give our team the opportunity to create even more effective and personalized training programs, based on the characteristics of the individual person. This makes us proud to say that we have taken another step towards our goal: to highlight the importance of the symbiotic relationship between health and physical activity."
Both companies presented the project at a press conference held at RiminiWellness last week.
About GetFIT Lifestyle
GetFIT is the first Italian fitness group with clubs in the city of Milan, Italy with over 30,000 active members. Through multifunctional, spacious and bright spaces, fitness rooms and swimming pools that coexist with thermarium and relaxation areas, GetFIT clubs are the ideal place to find fun, energy and relaxation. We select and train with passion all our team that represents with great professionalism our care for the reception and health of the body. We offer cutting-edge activities and design personalized paths to accompany our members towards the achievement of their goals. We have always chosen leading partners in the sector to take care of the well-being of the Milanese.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
VP of Investor Relations
+39 0862 191 0671
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Change in Aspo’s Group Executive Committee27.6.2022 10:20:00 CEST | Press release
Aspo Plc Stock exchange release June 27, 2022 at 11:20 a.m. Change in Aspo’s Group Executive Committee Heli Arantola, Managing Director of Aspo’s subsidiary Leipurin, has resigned to join another company. Arantola will leave the company in December at the latest, and the process of selecting her successor has begun. “I thank Heli for her excellent contribution to the modernization of Leipurin and transforming the company in the rapidly changing bakery and food industry. I wish her the best of luck in her future endeavors,” says Rolf Jansson, CEO of Aspo Group. Aspo Plc Rolf Jansson CEO Further information, please contact: Rolf Jansson, CEO, Aspo Plc, +358 400 600 264, email@example.com DISTRIBUTION: Nasdaq Helsinki Key media www.aspo.com Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of
Cool Company Ltd. – Mandatory Notification Of Trade27.6.2022 10:17:48 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 24 June 2022 acquired 7,035 shares in the Company at a price of NOK 89.307527 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,598,523 shares in the Company, equivalent to 38.99% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme27.6.2022 08:45:00 CEST | Press release
Company Announcement No. 43/2022 Copenhagen, 27 June 2022 Transactions in connection with share buy-back programme On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023. The
Basilea reports progress on the implementation of its strategy to focus on anti-infectives27.6.2022 07:15:00 CEST | Press release
ERADICATE phase 3 study exploring ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia (SAB) expected to report results shortlySeparate transactions for TTK/PLK1 inhibitor (BAL0891) and preclinical oncology projects expected to be concluded in H2 2022 No expansion of ongoing lisavanbulin clinical studies; exploring partnering opportunitiesDerazantinib rights to be transferred back to Merck & Co. by the end of 2022No material expenses related to oncology activities beyond 2022 and sustainable profitability expected in 2023Strategy implementation on track Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, June 27, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today an update on the progress made in the implementation of its strategic focus on anti-infectives. David Veitch, Chief Executive Officer, stated: “We have made significant progress in the implementation of our new strategy. Wit
Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release
REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens